178 related articles for article (PubMed ID: 17667528)
1. Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.
Tran CA; Burton L; Russom D; Wagner JR; Jensen MC; Forman SJ; DiGiusto DL
J Immunother; 2007 Sep; 30(6):644-54. PubMed ID: 17667528
[TBL] [Abstract][Full Text] [Related]
2. A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus-specific human CD4 and CD8 T lymphocytes.
Li Pira G; Bottone L; Ivaldi F; Pelizzoli R; Risso M; Tripodi G; Manca F
Transfusion; 2006 Dec; 46(12):2053-62. PubMed ID: 17176316
[TBL] [Abstract][Full Text] [Related]
3. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
4. Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems: potential applications for adoptive cellular immunoreconstitution.
Li Pira G; Ivaldi F; Tripodi G; Martinengo M; Manca F
J Immunother; 2008 Oct; 31(8):762-70. PubMed ID: 18779743
[TBL] [Abstract][Full Text] [Related]
5. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
6. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
7. GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL.
Hami LS; Green C; Leshinsky N; Markham E; Miller K; Craig S
Cytotherapy; 2004; 6(6):554-62. PubMed ID: 15764021
[TBL] [Abstract][Full Text] [Related]
8. Tetanus toxoid provides efficient T-cell help for the induction of HA-1(H) cytotoxic T cells.
Eiz-Vesper B; Horn PA; Daubert C; Khattab B; Blasczyk R
Transfusion; 2006 Jul; 46(7):1210-20. PubMed ID: 16836569
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Tam YK; Martinson JA; Doligosa K; Klingemann HG
Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer.
Giancola R; Olioso P; Di Riti M; Capone A; Contento A; Pompetti F; Iacone A
Transfusion; 2008 Apr; 48(4):629-39. PubMed ID: 18208417
[TBL] [Abstract][Full Text] [Related]
11. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
Li J; Mookerjee B; Wagner J
J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
[TBL] [Abstract][Full Text] [Related]
12. Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture.
Foster AE; Forrester K; Gottlieb DJ; Barton GW; Romagnoli JA; Bradstock KF
Biotechnol Bioeng; 2004 Jan; 85(2):138-46. PubMed ID: 14704996
[TBL] [Abstract][Full Text] [Related]
13. Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications.
Yuan J; Kendle R; Ireland J; Heller G; Sadelain M; Young JW; Rivière I
J Immunother; 2007 Sep; 30(6):634-43. PubMed ID: 17667527
[TBL] [Abstract][Full Text] [Related]
14. Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI).
Smetak M; Kimmel B; Birkmann J; Schaefer-Eckart K; Einsele H; Wilhelm M; Kunzmann V
Bone Marrow Transplant; 2008 Apr; 41(7):643-50. PubMed ID: 18037935
[TBL] [Abstract][Full Text] [Related]
15. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
16. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
Porter DL; June CH
Bone Marrow Transplant; 2005 May; 35(10):935-42. PubMed ID: 15806121
[TBL] [Abstract][Full Text] [Related]
17. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
[TBL] [Abstract][Full Text] [Related]
18. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.
Zandvliet ML; Falkenburg JH; Jedema I; Willemze R; Guchelaar HJ; Meij P
J Immunother; 2009 Jun; 32(5):513-23. PubMed ID: 19609244
[TBL] [Abstract][Full Text] [Related]
19. Human purified CD8+ T cells: Ex vivo expansion model to generate a maximum yield of functional cytotoxic cells.
Al-Shanti N; Aldahoudi Z
Immunol Invest; 2007; 36(1):85-104. PubMed ID: 17190652
[TBL] [Abstract][Full Text] [Related]
20. Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product.
Salot S; Laplace C; Saïagh S; Bercegeay S; Tenaud I; Cassidanius A; Romagne F; Dreno B; Tiollier J
J Immunol Methods; 2007 Sep; 326(1-2):63-75. PubMed ID: 17716681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
